Apparently, and I am still trying to confirm this but the source is very reliable, an affiliate TV station NBC reported early results from the Ovarian trial of 20%-30% response rates with no side-effects. This result would have been from the mono-therapy phase of the trial and is EXCELLENT bearing in mind that this response rate is better than recent cancer drugs recently approved by the FDA. The company is expecting much better results from the combination of phenoxodiol with cisplatin, a chemo therapy.
It looked to me that NVGN in the states was about to turn based upon the volume traded, and Marshall Edwards in the UK has been ticking up recently and the volume last night was 10,000 shares, which is a truckload for this stock in one single trading session.
I will try and find the TV report and post later. Looks like the price is about to snap, crackle and pop. Go you good thing.
I hold NRT
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held